Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,297 papers from all fields of science
Search
Sign In
Create Free Account
1.2 ML Plerixafor 20 MG/ML Injection [Mozobil]
Known as:
Mozobil 24 MG in 1.2 ML Injection
, Mozobil 24 MG per 1.2 ML Injection
, PLERIXAFOR 24 mg in 1.2 mL SUBCUTANEOUS SOLUTION [Mozobil]
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Hydrochloric Acid
Injection
Mozobil
Plerixafor
Expand
Broader (1)
Plerixafor Injection [Mozobil]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
A. Abiri
Medical Hypotheses
2018
Corpus ID: 51710941
2012
2012
Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience
J. Burger
2012
Corpus ID: 82722400
Chronic lymphocytic leukemia (CLL) cells express high levels of CXCR4, a seven transmembrane G-protein coupled chemokine receptor…
Expand
2011
2011
Efficacy and Safety of Hematopoietic Stem Cell Remobilization With Plerixafor (Mozobil®) + G-CSF in Patients With Germ Cell Tumor
J. Schriber
,
M. Horwitz
,
E. Libby
,
D. Huebner
,
P. Mody
,
P. Holman
2011
Corpus ID: 73029156
2010
2010
Plerixafor (Mozobil ®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma
K. Hintringer
2010
Corpus ID: 59352030
Patients suffering from hematological malignancies such as Non Hodgkin’s Lymphoma, Hodgkin Lymphoma or Multiple Myeloma are…
Expand
Review
2010
Review
2010
Plerixafor (Mozobil®) en pacients amb limfoma i mieloma múltiple
Comitè d’Avaluació de Medicaments d’Ús Hospitalari
2010
Corpus ID: 65263131
Limfoma; Mieloma multiple; Revisio sistematica; Lymphoma; Multiple Myeloma; Systematic review; Linfoma; Revision sistematica
2010
2010
Safety and Efficacy of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil ® ) + G-CSF In Pediatric Patients with Malignant Disorders
S. Shenoy
,
B. Asselin
,
+10 authors
P. Shaw
2010
Corpus ID: 208436426
Abstract 2245 Background: High dose chemo/radiotherapy followed by autologous hematopoietic stem cell (HSC) transplantation (HSCT…
Expand
2010
2010
A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide
T. Mark
,
A. Rossi
,
+6 authors
R. Niesvizky
2010
Corpus ID: 79368910
Abstract 2258 Background: Prior use of lenalidomide beyond 6 cycles of therapy in the treatment of multiple myeloma (MM) has been…
Expand
2010
2010
Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil®) + G-CSF In Adult Patients with Non-Hematologic Malignancies
M. Horwitz
,
E. Gorak
,
+4 authors
J. Schriber
2010
Corpus ID: 78636799
Abstract 2249 Background: Although high dose chemotherapy followed by autologous hematopoietic stem cell (HSC) transplantation is…
Expand
2009
2009
Mobilization with Plerixafor (Mozobil ®)Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in…
B. Bolwell
,
A. Nademanee
,
+6 authors
J. Dipersio
2009
Corpus ID: 78594583
Abstract 3224 Poster Board III-161 Background While most centers use 2 × 10 6 CD34+ cells/kg as the minimal cell dose for…
Expand
2009
2009
Plerixafor (Mozobil ®)Plus G-CSF Is Effective in Mobilizing Hematopoietic Stem Cells in Patients with Concurrent Thrombocytopenia Undergoing Autologous Hematopoietic Stem Cell Transplantation.
I. Micallef
,
E. Jacobsen
,
P. Shaughnessy
,
S. Marulkar
,
P. Mody
,
F. Rhee
2009
Corpus ID: 79313782
Abstract 3229 Poster Board III-166 Introduction Low platelet count prior to mobilization is a significant predictive factor for…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE